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Why you shouldn’t start  
beta-blockers before surgery 
A new meta-analysis finds that initiating beta-blockers 
before surgery increases patients’ risk of death. 
PRACTICE CHANGER
Do not routinely initiate beta-blockers in pa-
tients undergoing intermediate- or high-risk 
noncardiac surgery.  Beta-blockers appear to 
increase the 30-day risk of all-cause mortality.1 
StRENGtH oF RECoMMENDAtioN
A: Based on meta-analysis of 9 randomized 
controlled trials (RCTs).
Bouri S, Shun-Shin MJ, Cole GD, et al. Meta-analysis of secure 
randomised controlled trials of ß-blockade to prevent perioperative 
death in non-cardiac surgery. Heart. 2014;100:456-464.
ILLUSTRATIVE CASE
A 67-year-old woman with diabetes, hyper-
tension, and hyperlipidemia comes to your 
office for an evaluation before undergoing a 
total hip arthroplasty. She is not taking a beta-
blocker. Should you prescribe one?
Current guidelines from the American College of Cardiology Foundation (ACCF) and the American Heart As-
sociation (AHA) recommend starting beta-
blockers to prevent cardiac events in patients 
about to undergo intermediate- or high-risk 
surgery or vascular surgery who have a his-
tory of inducible ischemia, coronary artery 
disease (CAD), or at least one risk factor for 
CAD.2 However, the majority of the evidence 
for these guidelines, which were published in 
2009 and are in the process of being updated, 
came from the DECREASE (Dutch Echocar-
diographic Cardiac Risk Evaluation Applying 
Stress Echocardiography) trials, which have 
been discredited due to serious methodologi-
cal flaws, including falsified descriptions of 
how outcomes were determined and fictitious 
databases.3 A new meta-analysis by Bouri et al1 
that excluded the DECREASE trials found that 
although preoperative beta-blockers reduce 
the rate of certain nonfatal outcomes, they in-
crease the risk of death and stroke.  
STUDY SUMMARY
Multiple RCts find preop beta-blockers  
do more harm, than good
Bouri et al1 conducted a meta-analysis of 
published RCTs evaluating preoperative be-
ta-blockers vs placebo for patients undergo-
ing noncardiac surgery. Of the 11 studies that 
met eligibility criteria, 2 were the discredited 
DECREASE trials. Thus, Bouri et al1 analyzed 
9 high-quality RCTs that included 10,529 
patients.  
Most studies included patients undergoing 
vascular surgery. Some studies also included 
intra-abdominal, intrathoracic, neurosurgical, 
orthopedic, urologic, and gynecologic surger-
ies. Beta-blockers were started no more than 
a day before surgery and were discontinued 
at hospital discharge or up to 30 days postop. 
Metoprolol was used in 5 trials, bisoprolol in 
one trial, atenolol in 2 trials, and propranolol in 
one trial. The primary endpoint was all-cause 
mortality within 30 days. 
A total of 5264 patients were randomized 
to beta-blockers and 5265 to placebo. There 
were 162 deaths in the beta-blocker group and 
129 deaths in the placebo group.  Patients who 
received beta-blockers had a 27% increased 
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While  
beta-blockers 
protect against 
nonfatal Mis, 
they increase 
the risk of  
nonfatal strokes 
and death.
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risk of all-cause mortality (risk ratio [RR]=1.27; 
95% confidence interval [CI], 1.01-1.60; P=.04). 
The number needed to harm was 160. 
Six of the studies also evaluated rates of 
nonfatal myocardial infarction (MI), nonfa-
tal stroke, and hypotension. Beta-blockers 
lowered the risk of nonfatal MI (RR=.73; 95% 
CI, .61-.88; P=.001), but increased the risk of 
nonfatal stroke (RR=1.73; 95% CI, 1.00-2.99; 
P=.05) and hypotension (RR=1.51; 95% CI, 
1.37-1.67; P=.00001).
This meta-analysis was dominated by 
the 2008 Peri-Operative ISchemic Evaluation 
(POISE) trial, an RCT that compared placebo 
to extended-release metoprolol, 100 mg 2 to 
4 hours before surgery followed by 200 mg/d 
for 30 days, in 8351 patients with, or at risk for, 
atherosclerotic disease.4  While beta-blockers 
reduced the risk of MI and atrial fibrillation, 
they increased the risk of mortality and stroke, 
likely due to drug-induced hypotension. The 
slightly larger-than-typical doses of beta-
blockers used in the POISE study may have 
contributed to the excess mortality.
WHAT’S NEW
Avoiding beta-blockers in surgery  
patients will prevent deaths
Bouri et al1 found that while beta-blockers 
protect against nonfatal MIs, they increase the 
risk for nonfatal strokes and death. This new 
meta-analysis challenges the ACCF/AHA rec-
ommendations by suggesting that abandon-
ing the use of beta-blockers for preoperative 
patients who aren’t already taking them will 
prevent a substantial number of perioperative 
deaths. Bouri et al1  estimate that in the United 
Kingdom, where 47,286 deaths occur annually 
within 30 days of  intermediate or high-risk 
procedures, the number of iatrogenic deaths 
would drop by approximately 10,000 if beta-
blockers were not used.1 
CAVEATS
Don’t stop beta-blockers in patients  
who already take them
This meta-analysis did not evaluate out-
comes in patients who were already taking 
beta-blockers. Patients who are already on 
beta-blockers should continue to take them 
in the perioperative period, which is in line 
with current ACCF/AHA guidelines. 
CHALLENGES TO IMPLEMENTATION
Some physician may be reluctant  
to disregard published guidelines
Some physicians may not be comfortable 
ignoring the current ACCF/AHA guidelines 
that make a Class IIa recommendation (it 
is reasonable to administer this treatment) 
for the use of preoperative beta-blockade 
for patients at risk of cardiovascular events 
who were not previously taking a beta-
blocker. This updated meta-analysis ex-
cludes the discredited DECREASE trials 
and challenges us to act against these cur-
rent guidelines while we wait for updated 
recommendations.                JFP
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